GAM-05 Phase I trial in progress abstract has been accepted for poster presentation at ASCO, Chicago, May 29 – June 2, 2026. This acceptance underscores the growing recognition of Accanito’s approach to mitochondrial‑targeted oncology and the translational progress we are making in the clinic.
Thank you to our clinical partners, advisors, and team for driving this program forward with rigor and purpose. Looking forward to sharing early clinical insights with the oncology community in Chicago.
Contact Us
We welcome inquiries from partners, investors, and collaborators.
🌐 www.accanitotx.com
📧 uhayat@accanitotx.com
